C. E. Holmes, J. C. Huang, T. R. Pace, A. B. Howard and H. B. Muss, “Tamoxifen and Aromatase Inhibitors Differentially Affect Vascular Endothelial Growth Factor and Endostatin Levels in Women with Breast Cancer,” Clinical Cancer Research, Vol. 14, No. 10, 2008, 3070-3076. doi:10.1158/1078-0432.CCR-07-4640

has been cited by the following article:

• TITLE: Deep Venous Thrombosis in Breast Cancer Patients Using Tamoxifen, a Hypothesis

  AUTHORS: Meral Sayin, Bekir Hakan Bakkal

  KEYWORDS: Breast Cancer, Tamoxifen, Deep Venous Thrombosis, Hypothesis

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.5, December 31, 2011

  ABSTRACT: Breast cancer is the most frequently diagnosed cancer in women and systematic therapy is an essential component of disease. Hormonal therapy, cytotoxic chemotherapy and the more recently introduced biological therapies are routinely employed in the vast majority of patients. Several pharmaceuticals that affect the estrogenic pathways have been studied as chemopreventive agents. Tamoxifen is an anti-estrogenic drug used in the treatment of estrogen receptor positive breast cancer patients. One of the important side-effects of tamoxifen is thromboembolic events like deep venous thrombosis. Tamoxifen also causes an increase in mean platelet volume. We hypothesize that thromboembolic effect of tamoxifen is via increase of mean platelet volume.